Mutations within the E2 and NS5A protein in patients infected with hepatitis C virus type 3a and correlation with treatment response

Hepatology

Volumn 31, Issue 6, 2000, Pages 1360-1370

  Sarrazin, Christoph ^a   Kornetzky, Ilka ^a   Rüster, Brigitte ^a   Lee, Jung Hun ^a   Kronenberger, Bernd ^a   Bruch, Katharina ^a   Roth, W Kurt ^b   Zeuzem, Stefan ^a,c  

^a GOETHE UNIVERSITY   (Germany)

^b Inst Transfusionsmed IBH   (Germany)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; COMPLEMENTARY DNA; VIRUS RNA;

ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; GENE MUTATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; PHYLOGENY; PRIORITY JOURNAL; TREATMENT OUTCOME; VIREMIA; VIRUS HEPATITIS; VIRUS TYPING;

EID: 0034116306     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2000.7987     Document Type: Article

References (12)

1. Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander WJ, Hu PY, et al. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med 1992;327:1899-1905.
2. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:H85-1492.
3. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, et al. Randomised trial of Interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998;352:1426-1432.
4. Stark GR, Kerr IM, Williams BRG, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem 1998;67:227-264.
5. Gale MJ, Jr., Korth MJ, Katze MG. Repression of the PKR protein kinase by the hepatitis C virus NS5A protein: a potential mechanism of interferon resistance. Clin Diagn Virol 1998;10:157-162.
6. Gale M, Jr., Blakely CM, Kwieciszewski B, Tan SL, Dossett M, Tang NM, Korth MJ, et al. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. Mol Cell Biol 1998;18:5208-5218.
7. Gale MJ, Jr., Korth MJ, Tang NM, Tan SL, Hopkins DA, Dever TE, Polyak SJ, et al. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 1997;230:217-227.
8. Enomoto N, Sakuma I, Asahina V, Kurosaki M, Murakami T, Yamamoto C, Ogura Y, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus Ib infection. N Engl J Med 1996;334:77-81.
9. Sarrazin C, Berg T, Lee JH, Rüster B, Kronenberger B, Roth WK, Zeuzem S. Mutations in the protein kinase-binding domain of the NS5A protein in patients infected with hepatitis C virus type la are associated with treatment response. J Infect Dis 2000;181:432-441.
10. Chayama K, Tsubota A, Kobayashi M, Okamoto K, Hashimoto M, Miyano Y, Koike H, et al. Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype Ib hepatitis C virus infection. HEPATOLOGY 1997;25:745-749.
11. Kurosaki M, Enomoto N, Murakami T, Sakuma I, Asahina Y, Yamamoto C, Ikeda T, et al. Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy. HEPATOLOGY 1997;25:750-753.
12. Komatsu H, Fujisawa T, Inui A, Miyagawa Y, Onoue M. Mutations in the nonstructural protein 5A gene and response to interferon therapy in young patients with chronic hepatitis C virus 1b infection. J Med Virol 1997;53:361-365.